Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. svnanovax

SVNanoVax SIGNED

Structural Vaccinology in the design of bionanoparticles with multi-copy antigen display for vaccines with enhanced efficacy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 SVNanoVax project word cloud

Explore the words cloud of the SVNanoVax project. It provides you a very rough idea of what is the project "SVNanoVax" about.

host    malito    overcome    termed    promises    nada    pace    protein    candidates    meningococcal    enhanced    2014    antigen    functional    sepsis    offers    bexsero    pioneered    ordered    vaccines    arrays    antibodies    scarselli    potentiate    fhbp    broadly    quality    meningitidis    vaccine    combines    humans    2012    assembling    stably    escape    million    firstly    epitope    combine    bionanoparticles    ryan    neisseria    secondly    structure    prepared    coverage    diseases    vaccinology    innovative    monoclonal    optimized    2nd    aid    protective    protect    generate    1st    displaying    career    reducing    suitable    safe    safety    invasive    bnps    structural    2011    map    opportunity    antigens    immunogenicity    serogroup    nanobiology    mapping    variability    delany    copy    pathogens    lives    probability    bachmann    issue    display    immunogenic    breadth    disease    menb    infectious    2010    bactericidal    approved    epitopes    expertise    3d    bionanoparticle    self    2013    save    encompassing    bnp    structures    generation    sequence   

Project "SVNanoVax" data sheet

The following table provides information about the project.

Coordinator		 GLAXOSMITHKLINE VACCINES SRL 

Organization address
address: VIA FIORENTINA 1
city: SIENA
postcode: 53100
website: www.novartis.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Italy [IT]
 Total cost 168˙277 €
 EC max contribution 168˙277 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2015
 Duration (year-month-day) from 2015-06-15   to  2017-06-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLAXOSMITHKLINE VACCINES SRL IT (SIENA) coordinator 168˙277.00

Map

 Project objective

Vaccines are the most effective way to protect humans from infectious disease and may save over 2 million lives per year (Delany, 2013). A key issue for future vaccines is how to improve immunogenicity without reducing safety (Bachmann, 2010). Another challenge is that high antigen sequence variability enables pathogens to escape the host response. To overcome these challenges, this proposal combines Structural Vaccinology and bionanoparticle (BNP) design, to generate novel self-assembling BNPs with multi-copy antigen display for the development of safe vaccine antigens with enhanced immunogenicity and breadth of coverage.

We will generate antigen-BNPs for a 2nd generation vaccine against Neisseria meningitidis serogroup B (MenB), a major cause of sepsis and invasive disease (Pace, 2012). This research may also potentiate antigen-BNP technology suitable for other vaccines. Firstly, we will use functional (bactericidal) monoclonal antibodies to map the most protective epitopes on the 3D structures of two key MenB antigens, fHbp and NadA, which contribute strongly to our recently-approved 1st generation MenB vaccine, Bexsero (O’Ryan, 2014). To aid this, we have developed wide expertise in structure-focused epitope mapping (Malito, 2013). Secondly, we will design optimized antigens stably displaying the best epitopes, an approach that we have pioneered and termed ‘Structural Vaccinology’ (Scarselli, 2011). Finally, self-assembling protein bionanoparticles displaying ordered arrays of the optimized antigens will be prepared, in order to generate novel highly-immunogenic, broadly-protective MenB vaccine candidates.

The proposal offers an exciting career development opportunity encompassing novel high-quality research to combine and deliver the promises of Structural Vaccinology and nanobiology, with a high probability of success to generate innovative new vaccine antigens for products to protect humans against meningococcal and other infectious diseases.

 Publications

year authors and title journal last update
List of publications.
2016 Jacinto López-Sagaseta, Enrico Malito, Rino Rappuoli, Matthew J. Bottomley
Self-assembling protein nanoparticles in the design of vaccines
published pages: 58-68, ISSN: 2001-0370, DOI: 10.1016/j.csbj.2015.11.001 		Computational and Structural Biotechnology Journal 14 2019-06-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SVNANOVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SVNANOVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

IRF4 Degradation (2019)

Using a novel protein degradation approach to uncover IRF4-regulated genes in plasma cells

Read More  

SCAPA (2019)

Functional analysis of Alternative Polyadenylation during neuronal differentiation at single cell resolution

Read More